Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CNSX:ATTNYSE:HLNYSE:SDRNYSE:STJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATTAbattis BioceuticalsC$0.00C$0.05▼C$0.74N/AN/A1.42 million shsN/AHLHecla Mining$5.16+4.9%$5.51$4.41▼$7.68$3.26B1.5714.00 million shs28.55 million shsSDRSandRidge Mississippian Trust II$0.13$0.20▼$1.12$6.37M1.14172,872 shs434,700 shsSTJSt Jude Medical$80.82$0.00$48.83▼$84.00N/AN/A8.54 million shsN/A20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATTAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%HLHecla Mining+4.77%+13.66%-2.27%-12.17%+4.98%SDRSandRidge Mississippian Trust II0.00%0.00%0.00%0.00%0.00%STJSt Jude Medical0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/AN/AN/AHLHecla Mining4.1502 of 5 stars4.13.01.70.03.03.30.0SDRSandRidge Mississippian Trust IIN/AN/AN/AN/AN/AN/AN/AN/ASTJSt Jude MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATTAbattis Bioceuticals 0.00N/AN/AN/AHLHecla Mining 2.29Hold$7.2039.53% UpsideSDRSandRidge Mississippian Trust II 0.00N/AN/AN/ASTJSt Jude Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ATT, STJ, HL, and SDR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025HLHecla MiningTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$6.00 ➝ $5.005/5/2025HLHecla MiningBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$7.50 ➝ $5.503/21/2025HLHecla MiningNational Bank FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold3/11/2025HLHecla MiningTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.50 ➝ $5.502/21/2025HLHecla MiningTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $6.502/18/2025HLHecla MiningRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.60 ➝ $6.502/14/2025HLHecla MiningHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.50(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/AHLHecla Mining$1.00B3.26$0.38 per share13.69$3.23 per share1.60SDRSandRidge Mississippian Trust II$14.64M0.00N/A1.11$0.85 per share0.00STJSt Jude MedicalN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATTAbattis BioceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/AHLHecla Mining$35.80M$0.11103.2227.16N/A3.85%3.10%2.09%N/ASDRSandRidge Mississippian Trust II$10.32MN/A1.28N/AN/A66.85%21.99%21.99%N/ASTJSt Jude MedicalN/A$5.8713.77∞N/AN/AN/AN/AN/ALatest ATT, STJ, HL, and SDR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025HLHecla Mining$0.05$0.04-$0.01$0.05$238.50 million$261.34 million2/13/2025Q4 2024HLHecla Mining$0.05$0.04-$0.01$0.02$229.21 million$249.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATTAbattis BioceuticalsN/AN/AN/AN/AN/AHLHecla Mining$0.010.19%+2.17%9.09%N/ASDRSandRidge Mississippian Trust II$0.0522.12%N/AN/AN/ASTJSt Jude Medical$1.241.53%N/A21.12%N/ALatest ATT, STJ, HL, and SDR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025HLHecla Miningquarterly$0.00380.3%5/23/20255/23/20256/10/20252/13/2025HLHecla Miningquarterly$0.00380.3%3/10/20253/10/20253/24/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATTAbattis BioceuticalsN/AN/AN/AHLHecla Mining0.251.080.55SDRSandRidge Mississippian Trust IIN/AN/AN/ASTJSt Jude MedicalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATTAbattis BioceuticalsN/AHLHecla Mining63.01%SDRSandRidge Mississippian Trust II0.98%STJSt Jude Medical82.73%Insider OwnershipCompanyInsider OwnershipATTAbattis BioceuticalsN/AHLHecla Mining0.62%SDRSandRidge Mississippian Trust IIN/ASTJSt Jude Medical4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATTAbattis BioceuticalsN/AN/AN/ANot OptionableHLHecla Mining1,850632.56 million622.99 millionOptionableSDRSandRidge Mississippian Trust IIN/A49.73 millionN/AOptionableSTJSt Jude MedicalN/AN/AN/AOptionableATT, STJ, HL, and SDR HeadlinesRecent News About These CompaniesFamily shares experience at St. Jude Children’s Research HospitalMay 10 at 3:11 AM | wbko.comFighting Sickle Cell: How St. Jude and Donors Gave Avery a New Lease on LifeApril 29, 2025 | msn.comOne Step at a Time: How St. Jude and Supporters Helped Arielle Walk AgainApril 29, 2025 | msn.comSt. Jude Rock and Roll Music City marathon marks 25th anniversary this weekendApril 26, 2025 | newschannel5.comTopeka Dream Home helps St. Jude patients across the U.S.April 24, 2025 | msn.comLocal companies donate materials, labor for St. Jude Dream Home GivewayMarch 28, 2025 | msn.comA St. Jude superhero—this doctor has dedicated her life to treating cancer patientsMarch 22, 2025 | msn.comLocal representative fighting for St. Jude medical care in CharlestonMarch 18, 2025 | msn.com'St. Jude for pets': Decatur vet launching nonprofit research hospital to study diseases affecting humans and animalsMarch 12, 2025 | msn.comSt. Jude, UT, Vanderbilt push to keep NIH fundingFebruary 20, 2025 | dailymemphian.comProposed federal-funding cuts could come at a cost for St. Jude, UTHSCFebruary 12, 2025 | dailymemphian.comCould NIH funding cut affect St. Jude Children's Research Hospital? Here's what we knowFebruary 11, 2025 | msn.comNIH cuts could hurt research at St. Jude, UTFebruary 11, 2025 | msn.comSt. Jude creates new leadership roleJanuary 24, 2025 | beckershospitalreview.comEvidence still under review for suspects in 2023 shooting death of St. Jude doctorJanuary 16, 2025 | wreg.comOklahoma Family Bakes For A Cause To Help St. Jude Children's HospitalDecember 24, 2024 | newson6.comSt. Jude names executive vice president and chief administrative officerDecember 11, 2024 | msn.comSt. Jude Children’s Research Hospital plans new 16-story towerNovember 28, 2024 | msn.comSt. Jude files permit for 16-story advanced research center amid ongoing Memphis expansionNovember 27, 2024 | commercialappeal.com'It was just so shocking': St. Jude mother receives 16 automated bereavement emails in one dayNovember 27, 2024 | fox13memphis.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?3 High-Yield Dividend Stocks That Could Rally Near 52-Week LowsBy Chris Markoch | May 1, 2025View 3 High-Yield Dividend Stocks That Could Rally Near 52-Week LowsS&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry?By Jea Yu | April 23, 2025View S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry?AT&T, Verizon & T-Mobile: Who Won the Big 3 Telecom Battle in Q1?By Leo Miller | May 1, 2025View AT&T, Verizon & T-Mobile: Who Won the Big 3 Telecom Battle in Q1?3 Stocks to Watch as Bitcoin Nears $100k AgainBy Gabriel Osorio-Mazilli | May 5, 2025View 3 Stocks to Watch as Bitcoin Nears $100k AgainATT, STJ, HL, and SDR Company DescriptionsAbattis Bioceuticals CNSX:ATTAbattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.Hecla Mining NYSE:HL$5.16 +0.24 (+4.88%) As of 05/9/2025 03:53 PM EasternHecla Mining Company, together with its subsidiaries, provides precious and base metal properties in the United States, Canada, Japan, Korea, and China. The company mines for silver, gold, lead, and zinc concentrates, as well as carbon material containing silver and gold for custom smelters, metal traders, and third-party processors; and doré containing silver and gold. It flagship project is the Greens Creek mine located on Admiralty Island in southeast Alaska. Hecla Mining Company was incorporated in 1891 and is headquartered in Coeur d'Alene, Idaho.SandRidge Mississippian Trust II NYSE:SDRSandRidge Mississippian Trust II holds royalty interests in oil and natural gas properties. The company's properties are located in the Mississippian formation in Alfalfa, Grant, Kay, Noble, and Woods counties in northern Oklahoma and Barber; and Comanche, Harper, and Sumner counties in southern Kansas. As of December 31, 2018, its properties consisted of royalty interests in the initial wells and 173 additional wells. The company was founded in 2011 and is based in Houston, Texas.St Jude Medical NYSE:STJSt. Jude Medical, Inc. is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. The Company's product categories include tachycardia implantable cardioverter defibrillator systems; atrial fibrillation products (electrophysiology introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems); bradycardia pacemaker systems; vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography imaging products, vascular plugs, heart failure monitoring devices and other vascular accessories); structural heart products (heart valve replacement and repair products and structural heart defect devices); neuromodulation products, and Thoratec products. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
